Abstract | Congenital hearing loss (hearing loss that is present at birth) is one of the most prevalent chronic conditions in children. In the majority of developed countries, neonatal hearing screening programmes enable early detection; early intervention will prevent delays in speech and language development and has long-lasting beneficial effects on social and emotional development and quality of life. A diagnosis of hearing loss is usually followed by a search for an underlying aetiology. Congenital hearing loss might be attributed to environmental and prenatal factors, which prevail in low-income settings; congenital infections, particularly cytomegalovirus infection, are also a common risk factor for hearing loss. Genetic causes probably account for the majority of cases in developed countries; mutations can affect any component of the hearing pathway, in particular, inner ear homeostasis (endolymph production and maintenance) and mechano-electrical transduction (the conversion of a mechanical stimulus into electrochemical activity). Once the underlying cause of hearing loss is established, it might direct therapeutic decision making and guide prevention and (genetic) counselling. Management options include specific antimicrobial therapies, surgical treatment of craniofacial abnormalities and implantable or non-implantable hearing devices. An improved understanding of the pathophysiology and molecular mechanisms that underlie hearing loss and increased awareness of recent advances in genetic testing will promote the development of new treatment and screening strategies.
Congenital hearing loss -hearing loss that is present at birth -occurs when the ability of the ear to convert the vibratory mechanical energy of sound into the electrical energy of nerve impulses is impaired (FIG. 1) . Hearing loss is categorized according to the site of the lesion: in conductive hearing loss, the outer or middle ear is affected, and in sensorineural hearing loss, the inner ear, auditory nerve or central auditory pathway is affected. Mixed hearing loss is defined as conductive and sensorineural hearing loss. In conductive hearing loss, sound waves cannot propagate through the ear, either secondary to maldevelopment of the middle ear, the external ear or both, or following transient obstruction of the middle ear caused by effusion (as in the case of otitis media) 1 . Sensorineural hearing loss can be further subdivided into sensory hearing loss (when the hair cells are affected), central hearing loss (when the cause is located along the central auditory pathway) or auditory neuro pathy spectrum disorder 2 . Auditory neuropathy spectrum disorder includes a wide range of clinical conditions that are characterized by the presence of oto-acoustic emissions and a cochlear microphonic with abnormal or absent auditory brainstem responses, and results in impaired speech discrimination. Auditory neuropathy spectrum disorder can be caused by a primary lesion located in the inner hair cells or in the auditory nerve or intervening synapses and can also include damage to neuronal populations in the auditory pathway 3, 4 . In most developed countries, neonatal hearing screening programmes are available for this prevalent condition. These programmes aim to screen all newborn babies within 1 month of birth. Early diagnosis and subsequent early intervention and treatment promote improved developmental outcome later in childhood 5 . Because hearing loss can progress over time, neonatal hearing screening programmes might miss children with progressive hearing loss. Thus, repeated screening at regular intervals is advised for at-risk infants. Medical and supportive treatments of congenital hearing loss depend on aetiology and the type of hearing loss. Hearing loss is most often caused by genetic factors (including both non-syndromic forms, in which hearing loss is the only clinical feature, and syndromes, such as Usher syndrome or Jervell and LangeNielsen syndrome), craniofacial abnormalities or congenital infections.
In this Primer, we focus on unilateral and bilateral permanent congenital hearing loss, defined as hearing loss of ≥40 dB in the better hearing ear averaged over the . In countries without universal neonatal hearing screening programmes, prevalence estimates vary between 19 per 1,000 newborn babies in sub-Saharan Africa and up to 24 per 1,000 in South Asia 13 . The large difference in the prevalence estimates between high-income and low-income countries is only in part accounted for by the use of different diagnostic methods or criteria for hearing loss thresholds. The presence of risk factors is the most important predictor.
Risk factors
The Joint Committee on Infant Hearing from the American Academy of Pediatrics has identified several risk factors for congenital or late-onset childhood hearing loss 7 
. A positive family history of permanent congenital hearing loss is suggested as a risk factor, but the body of evidence for its relevance is low, as only 1.43% of children with a positive family history have hearing loss 14 . Admission to a neonatal intensive care unit is a relevant risk factor, with the prevalence of hearing loss increasing as gestational age and birth weight decrease (1.2% to 7.5% from gestational age of 31 weeks to 24 weeks and 1.4% to 4.8% from ≥1,500 g to <750 g birth weight) 15 . Necessary medical interventions (such as assisted ventilation, venous access and aminoglycoside use) while in the neonatal intensive care unit increase the likelihood of hearing loss. Duration of hospitaliza tion of ≥12 days and a history of treatment by high-frequency ventilation have also been identified as independent risk factors for hearing loss in this population 16 . In addition, delayed maturation of the auditory system has been postulated as a concern in infants who are hospitalized in this setting 17 .
In the majority of hearing-impaired children, hearing loss is due to genetic factors, most often a single gene defect 18 . These defects can have different modes of inheritance and different prevalences. Hearing loss is classified to reflect the presence (syndromic hearing loss; TABLE 1) or absence (non-syndromic hearing loss) of coexisting physical or laboratory findings. Nonsyndromic hearing loss is extremely heterogeneous. Autosomal recessive non-syndromic hearing loss, which accounts for 80% of genetic cases, is typically congenital, whereas autosomal dominant non-syndromic hearing loss, which accounts for the remaining 20% of cases, is often progressive with a later age of onset; X-linked or maternal mitochondrial DNA-related modes of inheritance are rare 19 . Although the frequency of causative genes varies across different populations and ethnicities, the most frequent genetic cause of severe-to-profound auto somal recessive non-syndromic hearing loss is a mutation in the gap junction protein β2 gene (GJB2) 20 . Mutations in this gene account for up to 50% of the autosomal recessive non-syndromic hearing loss cases in the white populations of Europe and the United States 20 . In some patients, clinical examination might point towards a syndromic cause. Physical findings, such as pre-auricular pits and tags, branchial cysts or fistulae or dystopia canthorum (the lateral displacement of the inner corners of the eyes, giving the appearance of a widened nasal bridge), heterochromia iridis and pigmentary abnormalities, might be associated with syndromes that are known to cause hearing loss, which must also be considered 21 . Over 400 of these syndromes have been described. The responsible genes for several syndromes are known and genetic testing is available for many of these 22 . Congenital infection is also an important risk factor, with congenital cytomegalovirus (CMV) infection standing out as the most common non-genetic cause of sensorineural hearing loss 23 . Whereas the prevalence of congenital CMV infection is 0.58% in developed countries, this figure increases to 1-6% in developing countries with a high rate of maternal seroprevalence 24 . The virus is shed in bodily fluids, such as urine, saliva and blood, and exposure to CMV is most commonly encountered through both sexual contact or contact with bodily fluids of young children with CMV infection. The risk of congenital hearing loss caused by an infection might largely depend on socioeconomic status (congenital CMV infection), the availability of prevention strategies, such as vaccination (congenital rubella virus infection), or hygienic measures (congenital toxoplasmosis). In countries without a rubella vaccination programme, congenital rubella virus infection is the leading environmental cause of congenital hearing loss 25 . All the aforementioned risk factors are included in surveys of the aetiology of congenital hearing loss, which divide causality between genetic and environmental factors. However, in most studies, a definitive cause cannot be identified in a considerable proportion of children with hearing loss [26] [27] [28] .
Mechanisms/pathophysiology
Congenital hearing loss can be divided into genetic and acquired forms. The mechanisms and pathophysiology of these two forms differ considerably.
Genetic congenital hearing loss
The study of hearing loss of genetic origin has greatly increased our understanding of normal auditory function and the pathophysiological processes that can disrupt it. Genetic mutations can affect any component of the hearing pathway. Most genes that are implicated in syndromic hearing loss are associated with an eponymous syndrome, whereas the loci that are linked to non-syndromic hearing loss are conventionally named using a prefix followed by a suffix integer: DFNA for autosomal dominant loci, DFNB for autosomal recessive loci and DFNX for X-linked loci. A regularly updated overview of all hearing loss-associated genes can be found online (http://hereditaryhearingloss.org). In this Primer, we concentrate on the genes that affect inner ear homeostasis (particularly endolymph production and maintenance) and mechano-electrical transduction (especially stereociliary bundle formation and function), as these genes are the most extensively studied.
Inner ear homeostasis: stria vascularis and endolymph.
At the cornerstone of inner ear homeostasis is the stria vascularis, which is situated on the lateral wall of the cochlear duct (FIG. 2) . This highly specialized tissue produces a unique fluid -the endolymph -that bathes the sensory hair cells of the inner ear and is crucial for auditory transduction. The unique ionic composition of the endolymph -a high concentration of K + ions (150 mM), a low concentration of Na + ions (1 mM) and a high positive endocochlear potential (+80 mV to 100 mV) -reflects the function of numerous channels, pumps and gap junctions. The stria vascularis consists of marginal, intermediate and basal cell layers. The marginal cells face the endolymph, and the intermediate and basal cells below communicate via gap junctions with each other and with the fibrocytes of the underlying spiral ligament (the thick periosteum that forms the outer wall of the cochlear duct) of the lateral wall. This network of gap junctions, whose proteins are encoded by GJB2 and GJB6, among others, facilitates ion transport between cells and couples the cells electrically. Mutations in GJB2 are the most common cause of severe-to-profound autosomal recessive congenital hearing loss in many populations 29 .
The intrastrial space (the intermediate cell layer and capillaries) is separated from the marginal cell layer and the basal cell layer by two tight junction barriers, which limit the passive movement of ions. Components of tight junctions include claudins, such as claudin 14, which is encoded by CLDN14, and MARVEL domaincontaining protein 2 (also known as tricellulin), which is encoded by MARVELD2; mutations in either gene give rise to autosomal recessive non-syndromic hearing loss in humans 30, 31 . Mutations in several other genes expressed in the stria vascularis that are important for ionic homeostasis in the endolymph result in various The ear is composed of three main parts: the outer, middle and inner ear. The outer ear includes the auricle and external auditory canal, and is separated from the middle ear by the tympanic membrane. The middle ear, a mucosal-lined, air-filled space, houses three bones (known as ossicles) -the malleus, incus and stapes -and bridges the external and inner ear. The inner ear is divided into two parts: the vestibular portion, which includes the vestibule and the three semicircular canals, saccule and utricle, and the cochlear portion, which contains the outer and inner hair cells of the sensory epithelium. The footplate of the stapes covers the oval window of the inner ear. The VIII cranial nerve (the auditory or cochlear nerve) links the inner ear with the brainstem. The Eustachian tube links the cavity of the middle ear to the pharynx, permitting the equalization of pressure on each side of the tympanic membrane. The ear converts the vibratory mechanical energy of sound into the electrical energy of nerve impulses. Sound is transmitted through the external auditory canal to the tympanic membrane and middle ear ossicles, where air vibration is translated and amplified to mechanical vibration. At the level of the stapes footplate, these mechanical vibrations are transmitted to the cochlea, which results in movement of the basilar membrane. Displacement of the basilar membrane alters the shape of the outer hair cells. This process mediates sound amplification and increases frequency specificity. Movement of the basilar membrane also results in the deflection of the stereocilia at the top of the inner hair cells, which generates a change in the electrical potential that is transmitted to the adjacent nerve fibres. Maintenance of the correct pH of the endolymph is also crucial for inner ear homeostasis. Mutations in genes encoding ion transporters and pumps that control the pH and ionic composition of the endolymph can cause deafness, including Pendred syndrome (resulting in hearing loss and goiter), distal renal tubular acidosis with deafness or non-syndromic early-onset severe-to-profound hearing loss, which are associated with an enlarged vestibular aqueduct. An enlarged vestibular aqueduct, whether syndromic (for example, Pendred syndrome) or non-syndromic, causes a fluctuating hearing loss in about one-third of patients 32 . These fluctuations might be associated with endolymphatic hydrops (an excessive accumulation of endolymph in the cochlea and the vestibular system), but the exact mechanism that causes hearing impairment and sudden drops in hearing is not well known 33 .
Mechano-electrical transduction: stereocilia. Several other forms of inherited hearing loss affect the morphology or function of the stereociliary bundle of the inner and outer hair cells, which are the cells that convert mechanical stimuli into electrical activity (FIG. 2) . Stereocilia are actin-rich projections on the apical surface of the hair cells that are arranged in a staircase-like manner and are tethered together by protein links. The tips of the tallest stereocilia of the outer hair cells are embedded in the overlying tectorial membrane, which is an acellular gel composed of radial collagen fibres embedded in non-collagenous glycoproteins, such as α-tectorin, β-tectorin, otogelin, otogelin-like protein, otolin 1 and carcinoembryonic antigen-related cell adhesion molecule 16. Thus, when the basilar membrane moves in response to sound, the stereocilia anchored in the hair cells move against the tectorial membrane causing a shearing motion.
This deflection of the stereocilia physically opens mechano-electrical transduction channels on the apical surface of the stereocilia (FIG. 2) and K + flows into the sensory hair cells along the electrochemical gradient. This K + influx depolarizes the hair cells, which leads to a cascade of events that triggers activity in the fibres of the auditory nerve. K + in the hair cells is subsequently released from the basolateral surface via channels that are encoded by the potassium voltage-gated channel subfamily Q member 4 gene (KCNQ4). Mutations in KCNQ4 cause a relatively common form of autosomal dominant non-syndromic progressive hearing loss.
Within the stereocilia, there are longitudinal actin fibres that are crosslinked for strength and rigidity by several proteins, one of which is espin, which is encoded by the ESPN gene. Mutations in ESPN cause either autosomal recessive non-syndromic hearing loss, with or without balance problems 34 , or autosomal dominant hearing loss, which is progressive and associated with normal balance 35 . At the base of the stereocilia, the actin filaments are tightly packed to form rootlets, which extend into the cell body. Mutations in TRIOBP, the gene encoding the cytoskeleton-associated TRIO and F-actinbinding protein, prevent actin filaments from organizing into dense bundles and cause a non-syndromic recessive hearing loss (DFNB28) 36 . At the other end of the stereo cilium, the tip links run from the apical surface of the shorter stereocilium to the lateral surface of its adjacent taller neighbouring stereocilium, where there is an electron-dense anchor composed of several interacting proteins that are important for hearing 37 (FIG. 2) . At the bottom of inner hair cells lies the ribbon synapse, which is a specialized type of neuronal synapse with thousands of vesicles that contain the neurotransmitter glutamate (released by Ca 2+ -dependent exocytosis of the vesicles). This structure allows rapid and sustained release of thousands of vesicles to accurately encode sound intensity and temporal acuity that is necessary for speech perception. In this exocytosis process, otoferlin (encoded by OTOF) plays an important part, and Otof-knockout mice have hearing loss because of the absence of exocytosis from inner hair cells 38 . Mutations in OTOF in humans can give rise to auditory neuropathy spectrum disorder (see above). CMV. CMV, which is a member of the Herpesviridae family, is the most common potentially disabling perinatal infectious agent 23 . Once an individual is infected, viral DNA is detectable in bodily fluids for months (CMV shedding), especially in the saliva and urine of young children, and represents a potential exposure risk for pregnant women 40 . The risk of congenital CMV infection is highest following primary infection during pregnancy, with a risk of vertical transmission in this setting of 32% 41 . However, in seropositive mothers, the risk of vertical transmission during reactivation or reinfection is only about 1.4%. Given that seropositivity for CMV infection in women of childbearing age in developed countries is approximately 50%, the incidence of congenital CMV infection is roughly 1 in every 100-200 live births 41 . The pathophysiological basis of sensorineural hearing loss following congenital CMV infection is unclear. Studies in the temporal bone have demonstrated inflammation and oedema of the cochlea and spiral ganglion, and viral antigens have been found in the spiral ganglion, organ of Corti, scala media and Reissner's membrane 42 . Evidence from mouse models suggests infection and direct cytolysis of components of the laby rinth, including hair cells 43, 44 . In another mouse model study of CMV inner ear pathogenesis, hearing loss was associated with a loss in spiral ganglion neurons following experimental challenge 45 . In addition to the direct cytolytic effect of viral infection, there is also evidence for immune injury, mediated by both the host immune response and the expression of viral genes encoding pro-inflammatory chemokines 46 . The virulence of the virus and the immune responses of the mother, fetus and placenta have a crucial role in the outcome 47 . Approximately 10% of CMVinfected neonates are symptomatic at birth and the risk of symptoms in the neonate is highest when maternal infection occurs around conception or within the first trimester of pregnancy 48 .
Acquired congenital hearing loss

Rubella virus.
Infants with congenital rubella virus infection are usually born at term, but often have a lower birth weight than non-infected newborn babies of the same gestational age. The most common complication of congenital rubella virus infection is hearing loss 49 . Other common findings are heart defects, catar acts, hepatosplenomegaly and microcephaly. Hearing loss, cataracts and congenital heart disease represent the classic triad of manifestations of congenital rubella syndrome 50 , although clinical signs can vary depending on the timing of fetal infection. In a prospective study of pregnant women with confirmed rubella virus infection, a range of rubellaassociated complications (including congenital heart disease and hearing loss) was observed in nine infants who were infected by 11 gestational weeks. 35% (9 out of 26) of infants infected between 13 and 16 gestational weeks . The acellular tectorial membrane overlies the sensory hair cells; mutations in genes encoding its various constituents can all cause hearing loss, although not all of these forms of genetic hearing loss are congenital in onset [140] [141] [142] [143] . The tip link that connects two adjacent stereocilia is located between the apical surface of the shorter one and the lateral surface of the taller one, whereas stereocilin connects the sides of the two stereocilia (top left inset). Mutations in the genes encoding components of the tip links and their interacting proteins cause syndromic and non-syndromic forms of congenital hearing loss. Unconventional myosin VIIa, a motor protein that moves along the stereociliary actin filaments, interacts with the PDZ domain-containing protein harmonin, Usher syndrome type 1G protein and cadherin 23 (REF. 144 ). Cadherin 23 is a long transmembrane molecule that homodimerizes and its large extracellular domains interact with homodimers of protocadherin 15 (REF. 145 ). These five tip link proteins form the 'Usher interactome' and mutations in their coding genes are responsible for Usher syndrome type 1 (TABLE 1) . Protocadherin 15 forms the lower half of the tip link. Its anchor includes a complex of the motor protein unconventional myosin XV, its cargo whirlin, epidermal growth factor receptor kinase substrate 8 and calcium and integrin-binding family member 2 (which is also associated with Usher syndrome type 1) [146] [147] [148] [149] . The MET channel at the lower tip link density might interact directly with protocadherin 15 (reviewed elsewhere 37 ). Tetraspan membrane protein of hair cell stereocilia, encoded by LHFPL5, is thought to link protocadherin 15 to the channel complex, and mutations in LHFPL5 can cause hearing loss in humans. The names of the genes encoding the proteins shown in the tip link inset are reported in parentheses. Adapted from REF. 150 had only one complication -hearing loss 49 . Hearing loss associated with congenital rubella syndrome might not occur until after birth 51 . The mechanism of rubella virus infection-induced hearing loss has not been fully explained, although the virus can cause direct cochlear damage, cell death in the organ of Corti and stria vascularis and alterations in the composition of the endolymph following strial damage 42, 52, 53 .
Diagnosis, screening and prevention
In the past century, targeted screening was performed exclusively in babies who were considered at high risk of hearing loss (that is, infants who were admitted to the neonatal intensive care unit and those with a family history of hearing loss or craniofacial anomalies). However, given the growing evidence that early detection of hearing loss is beneficial to child development, universal neonatal hearing screening programmes have been introduced. In many developed countries, universal neonatal hearing screening is now well established and typically uses a two-phase screening paradigm (that is, two electrophysiological measurements performed sequentially).
Assessment of hearing status
Screening usually consists of the measurement of oto-acoustic emissions (see below) repeated twice, measure ment of oto-acoustic emissions and automated auditory brainstem responses (see below), or measurement of automated auditory brainstem responses repeated twice 54 . Infants who do not pass the screening require appropriate audiological and medical evaluation to confirm the presence of hearing loss, ideally before 3 months of age 7 . However, passing the neonatal hearing test does not exclude progressive, late-onset and lesssevere congenital hearing loss (hearing loss of 30-40 dB), which is not detected in most neonatal hearing screening programmes. Children who pass neonatal hearing screening but have risk factors for hearing loss or whose parents express concern about their child's hearing abilities need regular follow-up, as hearing loss can develop later in life, depending on the underlying cause.
Upon referral from neonatal hearing screening, a complete audiometric assessment is required to confirm the presence of hearing loss and to assess its severity and laterality (unilateral or bilateral). The severity of the hearing impairment should be assessed based on the performance of the better hearing ear and averaged over 500, 1,000, 2,000 and 4,000 Hz. Hearing loss is classified based on laterality and severity as mild (hearing loss of 20-40 dB), moderate (41-70 dB), severe (71-95 dB) and profound (>95 dB) 55 . The audiometric assessment includes electrophysiological testing (oto-acoustic emissions, which estimate the function of outer hair cells, and auditory brainstem responses, which estimate the function of inner hair cells and the integrity of the auditory pathways) and behavioural testing (audiometry). In clinical practice, the functional integrity of the ear is assessed by different tests to cross-check the results of both physiological and behavioural measures.
Oto-acoustic emissions. Oto-acoustic emissions are sounds caused by the motion of the outer hair cells as they energetically respond to auditory stimulation 56 . Transient-evoked oto-acoustic emissions occur after the application of a click stimulus. The oscillatory sound pressure waveform that is seen in a transient-evoked oto-acoustic emission response corresponds to the motion of the tympanic membrane (eardrum) being pushed backwards and forwards by fluid pressure fluctu ations generated in the cochlea. Transientevoked oto-acoustic emission responses can give a frequency-specific indication of cochlear status and can be measured by a small probe in the external auditory canal. As their detection requires adequate sound transmission to and from the cochlea, oto-acoustic emissions should not be used as a stand-alone test for assessing normal-hearing status, but rather must be interpreted in the context of otoscopy, tympanometry and auditory brainstem response testing.
Auditory brainstem responses and auditory steadystate responses. Auditory brainstem responses are electrical potentials elicited by auditory stimuli that reflect neural activity at several discrete points along the auditory pathway. The activity is recorded from scalp electrodes using computer-averaging techniques. Click-induced or tone burst-induced auditory brainstem responses are most commonly used and are considered the gold standard for the objective assessment of hearing in infants and children of all ages. The obtained thresholds are typically within 10 dB of the behavioural auditory thresholds at the higher frequencies (2,000-4,000 Hz).
Auditory steady-state responses are elicited by AM/FM-modulated tonal stimuli. The stimulus is a continuous signal and can deliver higher average sound pressure levels than click stimuli, which makes auditory steady-state responses useful for obtaining threshold data in children with profound hearing loss (>90 dB). The absence of auditory steady-state response thresholds indicates no usable hearing and predicts poor hearing aid performance 57 . For all types of hearing loss, there is a close correlation between click auditory brainstem response and average auditory steady-state response thresholds at 2,000 and 4,000 Hz, with a difference of ≤10 dB between the thresholds measured with the two methods in the majority of cases 58 . Auditory steady-state responses are also useful to estimate the bone-conductive hearing thresholds and to distinguish conductive hearing loss from sensorineural hearing loss.
Audiometry. Visual re-enforcement audiometry can be used to test hearing in children 6-24 months of age. In children with adequate hearing, a new sound source will provoke an orientation reflex towards the sound. Skilled audiologists can obtain reliable results. Play audiometry is used in children 2-4 years of age, by means of conditioning them to respond to an auditory stimulus through play activities 59 . After 4 years of age, standard audiometry is typically used, with an air-conduction transducer (for example, an earphone) or a bone-conduction transducer (or both) (FIG. 3 ). An air-conduction transducer tests the integrity of the complete auditory system, whereas a bone-conduction transducer vibrates the skull, which directly stimulates the cochlea, bypassing the external and middle ear. Airconduction and bone-conduction thresholds, which are mostly obtained at octave frequencies of 250-8,000 Hz, differentiate sensorineural hearing loss and conductive hearing loss.
Aetiological work-up
Once a diagnosis of bilateral permanent congenital hearing loss is established, the search for an underlying aetiological diagnosis is required. The available guidelines include screening for congenital infections, imaging and genetic testing (see below) 28, [60] [61] [62] . First-line genetic tests are usually limited to screening for mutations in GJB2 and GJB6. The work-up is complemented by ophthalmological screening to check for ocular signs of congenital infection or syndrome-specific details, kidney ultrasonography to check for con genital malformations, electrocardiogram to rule out long QT syndrome (as is seen in Jervell and Lange-Nielsen syndrome) and other tests based on clinical findings. In unilateral hearing loss, the aetiological work-up can be limited to a thorough clinical examination for a syndromic cause of hearing loss, investigation of possible congenital infections and imaging of the inner ear.
Most available guidelines on the aetiological work-up of congenital hearing loss do not incorporate the diagnostic power of next-generation DNA sequencing technology and the use of comprehensive genetic testing using gene panels (see below). Comprehensive genetic testing using targeted genomic enrichment with massively parallel DNA sequencing has changed the diagnostic algorithm, and, in the future, the need for complementary examinations might be guided by the suspected diagnosis and the results of comprehensive genetic testing. A guideline published by the American College of Medical Genetics and Genomics recognizes the value of this new technology and recommends the use of gene panels 61 . In addition, the use of a sequential diagnostic algorithm (FIG. 4) based on the degree of hearing loss is advocated for children with bilateral congenital hearing loss 63 and, through a multi disciplinary approach, an aetiological factor can be identified in about half of the patients 28 .
An aetiological work-up for congenital hearing loss should be conducted for many reasons. It can provide parents with an answer as to why their child has hearing loss, allow accurate and personalized genetic counselling, provide relief from guilt in some cases and aid in management. A genetic diagnosis might provide an accurate estimate of risk for hearing loss in future children and might be helpful for parents in terms of family planning. Identifying the aetiology might help to choose appropriate therapeutic or management options (for example, hearing aids, cochlear implant ation or adapted educational needs), identify coexisting medical problems that need to be treated or monitored (especially when a syndromic genetic cause of hearing loss is found in a child who is referred as non-syndromic), secure preventable risk factors for future hearing deterior ation (for example, aminoglycoside use or head trauma) and might also predict the progression of hearing loss to a certain extent.
Genetic diagnostics. Genetic diagnosis always starts with family history and the construction of a pedigree. This information is essential to define the most probable mode of inheritance, which can in turn limit the list of potential causative genes. A patient without other affected family members might represent a case of autosomal recessive inheritance, but environmental causes of hearing loss must also be considered. DNA diagnostics for non-syndromic hearing loss is challenging, as there are numerous possible responsible genes and generally few diagnostic clues based on the phenotype. Thus, for a long time, diagnostic application of the identification of genes associated with hearing loss has lagged behind scientific progress. From 1998 to 2010, diagnostic laboratories in different countries typically analysed a handful of genes for non-syndromic hearing loss, including the most frequently mutated, GJB2. This approach typically identified the responsible gene in only 10-20% of patients with non-syndromic hearing loss. Technological developments, such as next-generation DNA sequencing, have enabled the simultaneous analysis of large numbers of genes. Using these techniques, several laboratories are now offering genetic testing for large panels of genes that are linked to syndromic or non-syndromic forms of hearing loss at an affordable price. Comprehensive genetic testing now has the highest diagnostic rate of any test in the evaluation of hearing loss once it is confirmed by audiometry results 64 . At present, a genetic diagnosis can also assist in predicting the success of specific clinical treatments. For example, in patients with auditory neuropathy spectrum disorder with mutations in OTOF, the function of the auditory nerve is expected to be preserved. However, the finding of cochlear nerve hypoplasia in some patients with auditory neuropathy spectrum disorder associated with mutations in the apoptosis-inducing factor, mitochondria-associated 1 gene (AIFM1) suggests that cochlear implantation in these patients might have limited success 65 . Thus, genetic diagnosis is useful in clinical decision making.
Diagnostics in acquired congenital hearing loss.
Any newborn baby with signs of congenital infection should be tested for CMV infection, as congenital CMV infection is the leading non-genetic cause of congenital hearing loss in developed countries. This infection should also be considered in children with hearing loss who are otherwise healthy and asymptomatic 66 . Signs and symptoms of CMV infection include intrauterine growth retardation, microcephaly and jaundice, with sensorineural hearing loss that is present in approximately 30% of symptomatic CMV-infected children 67 . In these instances, a diagnostic evaluation is indicated 48 . Prenatally, CMV PCR on amniotic fluid can confirm congenital CMV infection (the positive predictive value is close to 100%) 68 . After birth, urine, saliva or throat swab specimens of the newborn baby should be collected (samples must be collected within 3 weeks of birth, as viral shedding after this time point might reflect postnatally acquired, and not con genital, infection) and analysed 69 . In children undergoing evalu ation of the aetio logy of sensorineural hearing loss beyond 3 weeks of age, congenital CMV infection can only be confirmed in retrospect, by using stored dried newborn blood spots as the source of template for PCR-based diagnosis. In many developed countries, a blood sample is taken routinely during the first week of life for screening for meta bolic, endocrine and other disorders. The remaining blood is stored on dried blood spots. However, the availability of these samples depends on local storage policies; moreover, these blood spots have suboptimal diagnostic sensitivity, compared with saliva or urine samples that are obtained in 'real-time' . If congenital CMV infection is suspected, in addition to laboratory tests, brain imaging (cerebral ultrasonography or MRI), visual function assessment and hearing assessment are required. However, in 90% of newborn babies, congenital CMV infection is virtually asymptomatic. These children generally experience fewer neurodevelopmental problems than those who are symptomatic at birth, but 10% will nonetheless develop substantial sensorineural hearing loss at sometime in childhood 24 .
A definitive laboratory diagnosis of congenital rubella virus infection can usually only be made within 12 months from birth. Rubella virus infection is diagnosed if at least one of four criteria is met 70 : a positive anti-rubella IgM titre (possibly measured with enzyme immunoassays, such as enzyme-linked immunosorbent assay (ELISA)); a substantial rise in anti-rubella IgG titre 2-3 weeks after the acute phase of the infection or high titres that persist beyond what can be expected from passive maternal antibody transfer; the isolation of rubella virus in cultures from throat, nasal, blood, urine or cerebrospinal fluid specimens; or the detection of the virus by reverse transcriptase PCR in throat swabs, cerebrospinal fluid or surgical samples (from congenital cataracts, as the virus can be isolated from the lens).
Despite having neutralizing antibodies, a child infected with rubella virus can be infectious for months, which poses a hazard to susceptible individuals 71 . Occasionally, the virus can be isolated even after 12 months, for example, from lens material, where rubella virus can survive up to 3 years. In late-onset disease, the virus might also be present in the skin and lungs. Additional laboratory test results that can confirm the diagnosis of congenital rubella virus infection are thrombocytopenia, hyperbilirubinaemia and leukopenia. Although congenital rubella virus infection has become rare in the developed world owing to the eradication of the virus from the Western hemisphere, cases of imported disease can still be observed. Moreover, congenital rubella virus infection is still endemic in some low-income countries in the developing world, and, therefore, rubella virus infection should be considered in the diagnostic work-up of unexplained hearing loss if the infection cannot be excluded on historical or epidemiological grounds 60 .
Management
Therapeutic nonsurgical management of pathogenassociated hearing loss currently focuses on two key areas of intervention: specific antimicrobial therapies and anti-inflammatory therapies to mitigate the host's immune response to the infection and thereby reduce the damage to the cochlea. However, with a better understanding of infectious disease-related hearing loss, novel therapies might emerge, such as the use of free radical scavengers 72 , antioxidants 73 and nanoparticle-based systems 74 . Examples of non-medical support are special education and sign language [75] [76] [77] .
Nonsurgical treatment CMV.
Clinically manifest congenital CMV infection with central nervous system involvement requires antiviral treatment. Therapy with intravenous ganciclovir or the oral pro-drug of ganciclovir, valganciclovir, for 6 weeks was initially viewed as the preferred treatment option, although neutropenia was recognized as a possible adverse effect 78 . More recently, it has been demonstrated that administration of valganciclovir for 6 months starting in the first month of life improves neurodevelopmental outcomes and hearing in infants with symptomatic congenital CMV infection 79 . Other therapeutic options currently being explored include prophylactic vaccination, immunoglobulin therapy and prenatal antiviral therapy 68, 69, 80 . Children with congenital CMV infection require special follow-up with serial audiometry even if hearing is normal at birth, as they are at substantial risk for late-onset or progressive hearing loss 81 .
Rubella virus and other infections. Prepubertal vaccination can prevent congenital rubella virus infection.
Live attenuated rubella virus is typically administered in a trivalent formulation, combined with measles and . If a newborn baby fails the screening and bilateral congenital hearing loss is suspected, a comprehensive audiological and aetiological work-up is required. Audiological tests can confirm the presence of hearing loss and determine its type (conductive, sensorineural or auditory neuropathy spectrum disorder), laterality and severity. Genetic testing is an integral part of the aetiological work-up, as are the exploration of perinatal insults and the presence of congenital infections as possible causative agents. In particular, timely investigation for congenital cytomegalovirus (CMV) infection is essential, as it is the most common infectious aetiology of hearing loss. Virological identification of CMV must be made in the first 3 weeks of life to ensure that the infection was truly congenital and not postnatally acquired. Imaging studies are recommended in all cases of bilateral hearing loss of ≥60 dB or with craniofacial malformations 62 . Imaging examinations can rule out the presence of structural inner ear anomalies, which might occur as an independent entity, be part of a syndrome or have therapeutic implications. Certain inner ear anomalies may increase the risk for meningitis or may place the child at risk for sudden hearing loss (for example, an enlarged vestibular aqueduct) and require appropriate counselling. Imaging studies are a prerequisite before cochlear implantation to assess cochlear anatomy and confirm the presence of a cochlear nerve. A detailed assessment by a paediatric ophthalmologist is recommended, given the high prevalence (40-60%) of ophthalmological problems in hearing-impaired children Only limited data support a role for the medical management of other infections that can lead to sensorineural hearing loss (TABLE 3) . Congenital toxoplasmosis, caused by the parasite Toxoplasma gondii, is typically associated with intracranial calcifications, chorio retinitis and hydrocephalus 82 . However, the prevalence of hearing loss in congenital toxoplasmosis might be higher than appreciated, as the majority of infected children are asymptomatic at birth 83 . Maternal T. gondii infections are treated with spiramycin, and recommended therapies in infants with congenital infection include pyrimetha mine and sulfadiazine. Syphilis, caused by Treponema pallidum infection, is causally related to sensori neural hearing loss in both infants who have congenital infection and (albeit more rarely) children who acquire it postnatally.
All infants born to women with suspected or confirmed Zika virus infection during pregnancy should undergo neonatal hearing screening before hospital discharge. Infants with laboratory evidence of congenital Zika virus infection should be referred for hearing evaluation by auditory brainstem responses in the first month of life; if the test is normal, repeat automated auditory brainstem response testing is recommended at 4-6 months of age 84 .
Restoration of hearing
Restoration of hearing is achieved by implantable or non-implantable hearing devices, including conventional hearing aids, cochlear implants and boneanchored hearing aids; their basic principles and working mechanisms are illustrated in FIG. 5. Conventional hearing aids. In most patients with sensori neural hearing loss, auditory rehabilitation consists of conventional hearing aids. Even in some patients with conductive hearing loss, hearing aids are the principal treatment, especially when medical or surgical options are not feasible. Continued developments in signal processing and increasing miniaturization have increased the performance of hearing aids and their acceptance among patients 85, 86 . For example, the max imum gains for digital in-the-ear, in-the-canal and completely-in-canal aids are about 55-65 dB, 45-55 dB and 35-50 dB, respectively. Nearly all hearing aids are digital and programmable and, therefore, can be customized to the characteristics of the patient's hearing 86 . Despite these advantages, hearing aids have several limitations, including lack of sufficient perceived benefit, high expenses, complications (such as occlusion of the external auditory canal) and cosmetic concerns [87] [88] [89] . As a result, only one in five eligible adults actually uses a hearing aid 90, 91 . By contrast, the use of hearing aids in children is much more widespread, because of the recognized crucial importance of early intervention for hearing loss management that is made possible by universal neonatal hearing screening 92 . The limitations of conventional hearing aids have generated enthusiasm for implantable middle ear hearing technologies that attempt to solve many of the difficulties imposed by conventional aids. Implants couple vibration stimuli directly to the inner ear through multiple ways, thereby offering higher gains and reduced sound distortion than conventional aids. However, the need for surgery, high costs and lack of insurance reimbursement have limited their widespread implementation [93] [94] [95] .
Cochlear implants. For patients with mild-to-severe sensorineural hearing loss, conventional hearing aids can provide excellent hearing rehabilitation. However, once hearing loss becomes severe to profound, these . Furthermore, cochlear implantation is no longer limited to patients with severe-to-profound hearing loss and is now suitable for patients with relatively good low-frequency hearing but poor high-frequency hearing. In these patients, 'hybrid' or 'electro-acoustic stimulation' implants are used, which offer considerably improved sound quality in combination with natural hearing in the low frequencies 97, 98 . These implants are very nearly identical to standard cochlear implants, although they have smaller diameter electrode arrays, which are only inserted into the basal turn of the cochlea.
Cochlear implantation is now the standard of care for children with profound congenital hearing loss whose parents choose to use oral communication. With the availability of screening and early detection, the age at first implantation has progressively declined and many children are now fitted with an implant before their first birthday 99 . As bilateral cochlear implantation has been shown to be superior to unilateral cochlear implantation in terms of vocabulary outcomes, speech perception and sound localization, a growing number of countries provide reimbursement for a second implant in children. The outcome of cochlear implantation in children might depend on the underlying aetiology and associated comorbidities, especially in children with syndromic hearing loss or associated disabilities 100, 101 . Genetic testing is an important tool for predicting the outcomes of cochlear implantation or electro-acoustic stimulation and is useful for choosing the appropriate treatment [102] [103] [104] [105] .
Bone-anchored hearing aids. Improvement or restoration of hearing in conductive hearing loss might be challenging in children with congenital anomalies, such as the spectrum of atresia (abnormal narrowing or absence) of the external auditory canal. Children with atresia of the external auditory canal with minimal or no involvement of the ossicular chain can benefit from microsurgical intervention, although surgery is usually postponed until ≥6 years of age 106 . In children with complete bony atresia, conventional air-conduction hearing aids are not an option. When surgical reconstruction is not possible or declined by the family, bone-anchored hearing aids are indicated 106, 107 . However, compared with adults, children have a higher incidence of complications, including non-osseointegration (as high as 15%) 108 . A meta-analysis of bone-anchored implant complications has demonstrated skin reactions in 2.4-38.1% of cases, failure of osseointegration up to 18% and revision surgery rates up to 44% 109 . These results are consistent across studies. Underlying cochlear function is an important determinant of benefit with bone-anchored implants; in general, children Figure 5 | Non-medical treatments for hearing loss. a | A conventional hearing aid converts environmental sounds into amplified sounds. A hard case is worn behind the auricle and contains all the electronic parts (a microphone, amplifier and battery). A sound is picked up by a microphone and converted into an electrical signal that corresponds to the pressure variation produced by the sound. This signal is then amplified and delivered to a speaker that converts the amplified electrical signal back into sound. The speaker sends the sound signal to the tympanic membrane by a slim tube that connects the hearing aid to an earmold that fits in the external auditory canal. b | A cochlear implant converts sounds into electrical signals and is composed of different parts. A microphone (1) picks up environmental sounds and transmits them to a speech processor (2) . Through a magnetic coil (3) , acoustic signals are transmitted from the speech processor to a subcutaneously implanted receiver-stimulator (4) that converts the acoustic signal into electric impulses. An electrode array (5) that is placed in the scala tympani of the cochlea directly stimulates the auditory nerve (6) . c | A bone-anchored hearing aid converts a sound signal into microvibrations: it uses the principle of bone conduction to directly stimulate the cochlear fluids by vibrating the skull behind the ear at auditory frequencies. A titanium screw (the implant) is surgically anchored in the bone and becomes fixed through a process called osseointegration. The implant is connected to a sound transducer by means of an abutment (connector). The sound transducer captures the sound, converts it into vibrations and sends them to the implant. The implant then transmits the vibrations through the bone directly to the inner ear. In the most recent bone-anchored hearing aid systems, the abutment is replaced by a magnetic connection. with average pure-tone bone-conduction thresholds of <45 dB receive excellent benefit from bone-anchored hearing implants, whereas those with averages of 45-60 dB have intermediate benefit.
An additional important advantage of boneanchored hearing aids is their rehabilitation of unilateral sensorineural hearing loss [110] [111] [112] . Placed in the hearing-impaired ear, these devices expand the sound field for the patient and substantially improve speech understanding in noise, similar to a contralateral routing of offside signal hearing aid or a transcranial system. In these situations, the processor placed on the side of the hearing-impaired ear acts as a microphone, which then directs the sound to the hearing ear directly through the skull, whereas a contralateral routing of offside signal hearing aid will transmit that sound wirelessly to a hearing aid that is worn in the normal-hearing ear. An increasing body of evidence has clearly demonstrated that the primary benefit is improved hearing in noise, whereas the implants provide little or no objective benefit in sound localization.
Other surgical treatment options. Both implant able and non-implantable hearing devices offer excellent rehabilita tive options for patients with hearing loss. Depending on the nature and extent of hearing loss, other surgical options might also be available. For patients who have conductive hearing loss due to abnormalities of the external auditory canal (for example, congenital aural atresia), tympanic membrane (from acute or chronic infections) or ossicles (from congenital or acquired fix ation of the ossicles), surgery can be attempted to correct these defects, often with excellent functional results 113 .
Quality of life
Hearing-impaired children who do not receive early intervention and rehabilitation will fall behind their normal-hearing peers in reading skills, cognition and socio-emotional development. This gap might in turn result in modest educational achievements and employment levels in adulthood 114 . Speech development is impaired by delayed age at diagnosis of hearing loss. Children whose hearing loss is identified by 6 months of age have significantly better receptive and expressive skills than children whose hearing loss is identified later 5 . The age-at-diagnosis effect is evident across age, sex, socioeconomic status, ethnicity, cognitive status, degree of hearing loss, mode of communication and the presence or absence of other disabilities 115 . The positive effect on language outcomes of early confirmation of permanent childhood hearing impairment that is observed in children at primary school age is also found in teenagers. Moreover, the gap in reading skills between children with early confirmed permanent childhood hearing impairment and children with later confirmed impairment widens with age 116 . Developmental impairment is measurable as early as 3 years of age. The DECIBEL study compared development and quality of life for children whose hearing loss had been identified through a neonatal hearing screening programme (that is, before 2 weeks of age) and children whose hearing loss had been diagnosed after a distraction hearing programme performed at 9 months of age 117 . Children in the neonatal screening programme received hearing amplification 13 months earlier than children in the distraction hearing screening. Quality-of-life scores (which were assessed using the Pediatric Quality of Life Inventory) at 3-5 years of age were significantly better in children with permanent hearing impairment who were identified in the neonatal screening programme 117, 118 . Factors that might contribute to the delay between diagnosis and intervention include: time for reflection requested by the child's parents, cultural considerations, doubts about the degree of hearing loss and the benefits of hearing amplification, acceptance and wearing of hearing aids, and practical and technical considerations.
The introduction of hearing aids before 6 months of age will improve subsequent hearing development and is now considered a standard goal in the management of children with bilateral hearing loss 7 .
Outlook
The biggest challenge in the short term in congenital hearing loss is the better prevention of infectious aetiologies. In the long term, it is moderating the effects of genetic hearing loss.
CMV-associated hearing loss
The complex correlations among CMV-induced inflammation, local and systemic host response and the development and progression of sensorineural hearing loss are not adequately understood. Ribosomal profiling has shown that the protein-coding capacity of CMV includes up to 751 open reading frames (including splice variants), most of which are translated into small proteins of unknown function that are predicted to be shorter than 100 amino acids in length 119 . Because CMV depends on inflammation for reactivation, some of these proteins might simultaneously induce local inflammation and protect the reactivated virus from the host's immune recognition and destruction 120 . The CMV genome includes multiple genes associated with immune evasion, which promote persistence of the infection and preclude its clearance 43, 121 . Furthermore, the presence of multiple epitopes across CMV strains means that IgG seropositivity does not completely guarantee protection against reinfection, which increases the challenge of developing a vaccine to completely prevent congenital transmission and its attendant sequelae [122] [123] [124] . 125 . One of the factors that complicate the evaluation of the pathogenicity of variants is the ethnicity of the patients, as genetic vari ants often have different frequencies in different ethni cities. Concerted efforts should be made to sample multiple distinct ethnicities, as these data are of great importance for assessing the possible pathogenicity of identified variants.
Improving genetic diagnoses
Integration of the patient's hearing loss phenotype with the underlying genotype is essential. Except for GJB2, no large-scale genotype-phenotype studies have been performed 20 . However, these genotypephenotype correlations are of great importance for the interpretation of the results of genetic testing, as they provide crucial information about the possible pathogenicity of genetic variants. Complex modelling tools, such as AudioGene (http://audiogene.eng.uiowa.edu), offer several enhancements to traditional audiometry and might provide a better tool with which to dissect complex genotype-phenotype interrelationships 126 .
Hearing preservation and restoration
Emerging therapies for hearing loss can be broadly subclassified as hearing preservation or hearing restoration strategies 127, 128 . Hearing preservation would probably be easier to achieve than hearing restoration; preservation strategies seek to promote hair cell survival and correct protein defects before complete and irreversible hair cell damage occurs. Once hair cells have died, hearing restoration strategies are required, with treatment options depending on the condition of the remaining supporting cells.
Thanks to progress in genetic testing, it is possible to identify groups of patient with gene-specific mutations. Studies aimed at elucidating the broader effects of mutations at the gene level are needed to identify pathways, interactions and crosstalk, which in turn are likely to provide new insights into hearing preservation strategies.
It might be possible to transdifferentiate healthy support ing cells into hair cells in the cochlea 129 . However, for transdifferentiated hair cells to function properly, they must also integrate into their local micro environment. Thus, even if the hurdle of transdifferentiation were overcome, other substantial challenges would remain. Although transdifferentiation therapy might be success ful, several problems have to be resolved before its clinical application is contemplated 128 . For example, transdifferentiated hair cells often are not completely normal and instead exhibit a phenotype that is intermediate between a hair cell and a supporting cell. With more-severe inner ear damage, the response to trans differentiation therapy is not very good, suggesting that a better understanding of the mechanism of hair cell death (apoptosis or necrosis, or both) is crucial 130 . Once hair cells are lost, the basilar membrane becomes lined with non-sensory cells, making protective therapies, even at this late stage, important to prevent transition to a flat epithelium 128 .
Drug delivery and therapeutic targets
Pharmacological treatment to enhance self-repair of hair cells (hearing preservation) and transdifferentiation of supporting cells (hearing restoration) will require high throughput, rapid screening systems to optimize rational drug design and the development of drug delivery systems for the cochlea. Studies have demonstrated the efficiency of zebrafish models in drug design 131 and middle ear-infused, gelatine-based hydrogels seem promising as a means to deliver drugs to the cochlea 132 . A novel intra-tympanic polymer gel delivery system has been evaluated and tested as a strategy for antiviral drug delivery in a guinea pig model 133 and holds promise for providing antiviral therapy to the CMV-infected cochlea while sparing the patient the substantial toxicities that are associated with systemic delivery of antiviral agents.
Neonatal hearing screening programmes
Over 50% of cases of permanent childhood hearing impairment can be detected shortly after birth through a neonatal hearing screening programme. However, passing the neonatal screening does not guarantee normal hearing in childhood and is not a valid reason to disregard parental suspicion of hearing impairment. Progressive or late-onset hearing impairment, as seen with congenital CMV infection or in some genetic conditions, is undetected by neonatal screening programmes. Thus, postnatal identification of childhood hearing loss will remain dependent on the interaction between parents and professionals. All individuals who work with children (for example, teachers and health care providers) should monitor the child's general development and especially language development.
Other limitations of neonatal hearing screenings are related to the sensitivity and specificity of the screening method, coverage and follow-up after a referral from screening. For example, although universal neonatal hearing screening in Flanders, Belgium, has high sensitiv ity (94.02%) and specificity (99.96%) 134 , false-positive test results might cause unnecessary anxiety in parents during the vulnerable first weeks of their newborn infant's life. Coverage might be a concern in low-income countries where hearing screening programmes are not available or access to them is limited. In many universal neonatal hearing screening programmes, the progress from screening to intervention is the weakest point of the health care pathway, with the proportion of children lost to follow-up (and treatment) as high as 52% of those referred 135 .
An increasing body of evidence shows that universal neonatal hearing screening is not only beneficial for the child's development and quality of life but is also costeffective. The costs of neonatal hearing screening are comparable with other newborn screening programmes and the benefits are expected to outweigh the costs 7, 136 . An economic analysis has confirmed that both universal and targeted screenings for congenital CMV infection are cost-effective, an observation that should help to drive the expansion of screening programmes for this infectious cause of hearing loss in infants
